Selective lymph node dissection for early-stage lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of selective lymph node dissection in patients with cT1N0M0 invasive non-small cell lung cancer (NSCLC) that has a tumor-to-lung ratio greater than 0.5 and is located in the apical segment. The study will assess the 5-year overall survival rates, as well as the rates of post-operative lymph node metastasis and recurrence-free survival. Participants will undergo the surgical procedure of selective lymph node dissection to determine its therapeutic benefits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who sign the informed consent form and are willing to complete the study according to the plan;
2. Aged from 18 to 80 years old;
3. ECOG equals 0 or 1;
4. Not receiving lung cancer surgery before;
5. Resectable peripheral cT1N0M0 tumors with CTR\>0.5 located in the apical segment;
6. Non-lepidic predominant invasive NSCLC dignosed by frozen section;
7. Not receiving chemotherapy or radiotherapy before.

Exclusion Criteria:

1. Not cT1N0M0;
2. Nodules not located in the apical segment or CTR≤0.5;
3. Pre-invasive lung adenocarcinoma, lepidic predominant adenocarcinoma, or not lung adenocarcinoma diagnosed cytologically or pathologically;
4. Receiving lung cancer surgery before;
5. Receiving radiotherapy or chemotherapy.

Where it's running

• Chaoqiang Deng
  Shanghai, Please Select, China Recruiting

Study contacts

• Principal investigator: Haiquan Chen, M.D. — Fudan University
• Study coordinator: Chaoqiang Deng, M.D.
• Email: fdudengcq@163.com
• Phone: +86-13122677592

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions

  This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.

  Recruiting Sheba Medical Center · Ramat Gan, Israel · NCT07636252

• Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib

  This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá · NCT07633626

• Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain

  This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Chongqing, Chongqing Municipality and 2 other locations · NCT07481786

• 7-day low-carb, high-fat (ketogenic) diet to improve FDG PET/CT detection of lepidic lung adenocarcinoma

  This trial will test whether a personalized 7-day ketogenic (low-carb, high-fat) diet before an FDG PET/CT can improve detection of lepidic-predominant lung adenocarcinoma in adults with a suspicious lung nodule or confirmed diagnosis.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Torino (TO) · NCT07479095

• Partial high-dose tumor irradiation combined with immunotherapy for unresectable lung adenocarcinoma

  This trial will try giving very high-dose radiation to the central part of large, unresectable lung adenocarcinomas while preserving the surrounding immune tissue and pairing that with an immune checkpoint drug for patients who have no remaining standard treatment options.

  Recruiting Karl Landsteiner University of Health Sciences · Krems, Austria · NCT07423169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.